Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome

被引：5

作者：

del-Pino, Rodrigo Aguirre ^{[1
,2
]}

Monahan, Rory C. ^{[1
,3
]}

Huizinga, Tom W. J. ^{[1
]}

Eikenboom, Jeroen ^{[4
]}

Steup-Beekman, Gerda M. ^{[1
,5
]}

机构：

[1] Leiden Univ Med Ctr, Dept Rheumatol, Leiden, Netherlands

[2] A Coruna Univ Hosp CHUAC, Div Rheumatol, Xubias Arriba 84, Galicia 15006, Spain

[3] Leiden Univ Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands

[4] Leiden Univ Med Ctr, Dept Internal Med, Div Thrombosis & Hemostasis, Leiden, Netherlands

[5] Haaglanden Med Ctr, Dept Rheumatol, The Hague, Netherlands

来源：

SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2024年 / 50卷 / 06期

关键词：

antiphospholipid syndrome; antiphospholipid antibody; thrombosis; risk factor; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; VENOUS THROMBOEMBOLISM; SYNDROME SCORE; FOLLOW-UP; VITAMIN-D; CLASSIFICATION CRITERIA; CARDIOVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; RHEUMATOID-ARTHRITIS;

D O I：

10.1055/s-0043-1776910

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Persistence of serum antiphospholipid antibodies (aPL) is associated with a high thrombotic risk, both arterial and venous, and with pregnancy complications. Due to the potential morbidity and mortality associated with the presence of aPL, identifying and recognizing risk factors for the development of aPL and thrombosis in aPL carriers may help to prevent and reduce the burden of disease. Multiple elements are involved in the pathomechanism of aPL development and aPL-related thrombosis such as genetics, malignancy, and infections. This review will address the role of both well-known risk factors and their evolution, and of emerging risk factors, including COVID-19, in the development of aPL and thrombosis in aPL carriers.

引用

页码：817 / 828

页数：12

共 50 条

[21] Accelerated atheroma, antiphospholipid antibodies, and the antiphospholipid syndrome
George, J
Haratz, D
Shoenfeld, Y
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (03) : 603 - +
[22] Antiphospholipid antibodies, antiphospholipid syndrome and suprarenal haematoma
Alijotas-Reig, Jaume
MEDICINA CLINICA, 2008, 131 (19): : 759 - 759
[23] MECHANISMS OF ACTION OF ANTIPHOSPHOLIPID ANTIBODIES IN THE ANTIPHOSPHOLIPID SYNDROME
ARON, AL
GHARAVI, AE
SHOENFELD, Y
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1995, 106 (01) : 8 - 12
[24] Managing antiphospholipid antibodies and antiphospholipid syndrome in children
Kamat, Anil, V
D'Cruz, David P.
Hunt, Beverley J.
HAEMATOLOGICA, 2006, 91 (12) : 1674 - 1680
[25] Antiphospholipid antibodies, antiphospholipid syndrome and pregnancy management
Nossent, Hans
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 : 17 - 17
[26] Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome
Devreese, Katrien M. J.
Zuily, Stephane
Meroni, Pier Luigi
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2021, 4
[27] Antiphospholipid antibodies and reproduction: The antiphospholipid antibody syndrome
Kutteh, WH
Rote, NS
Silver, R
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1999, 41 (02): : 133 - 152
[28] Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
T Koike
Arthritis Res Ther, 5
[29] ANTIPHOSPHOLIPID ANTIBODIES AND ANTIPHOSPHOLIPID SYNDROME: DIAGNOSIS AND MANAGEMENT
Garcia-Garcia, C.
ACTAS DERMO-SIFILIOGRAFICAS, 2007, 98 (01): : 16 - 23
[30] Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy
Lee, Eunyoung Emily
Jun, Jong Kwan
Lee, Eun Bong
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (04)

← 1 2 3 4 5 →